The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients

Mazen T. Elkurd; Laxman B. Bahroo; Rajesh Pahwa

doi:10.2217/nmt-2018-0001

The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients

Mazen T. Elkurd, Laxman B. Bahroo, Rajesh Pahwa

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.

Original language	English (US)
Pages (from-to)	73-80
Number of pages	8
Journal	Neurodegenerative disease management
Volume	8
Issue number	2
DOIs	https://doi.org/10.2217/nmt-2018-0001
State	Published - Apr 1 2018
Externally published	Yes

Keywords

ADS-5102
amantadine
amantadine ER
EASE
gutamate antagonist
levodopa-induced dyskinesia
NMDA antagonist
OFF time
Parkinson's disease
Unified Dyskinesia Rating Scale

ASJC Scopus subject areas

General Medicine

Access to Document

10.2217/nmt-2018-0001

Cite this

@article{a6d8b2a4e2444acf8990f55703ddd59e,

title = "The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients",

abstract = "Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.",

keywords = "ADS-5102, amantadine, amantadine ER, EASE, gutamate antagonist, levodopa-induced dyskinesia, NMDA antagonist, OFF time, Parkinson's disease, Unified Dyskinesia Rating Scale",

author = "Elkurd, {Mazen T.} and Bahroo, {Laxman B.} and Rajesh Pahwa",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2018",

month = apr,

day = "1",

doi = "10.2217/nmt-2018-0001",

language = "English (US)",

volume = "8",

pages = "73--80",

journal = "Neurodegenerative disease management",

issn = "1758-2024",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients

AU - Elkurd, Mazen T.

AU - Bahroo, Laxman B.

AU - Pahwa, Rajesh

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.

AB - Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.

KW - ADS-5102

KW - amantadine

KW - amantadine ER

KW - EASE

KW - gutamate antagonist

KW - levodopa-induced dyskinesia

KW - NMDA antagonist

KW - OFF time

KW - Parkinson's disease

KW - Unified Dyskinesia Rating Scale

UR - http://www.scopus.com/inward/record.url?scp=85054350584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054350584&partnerID=8YFLogxK

U2 - 10.2217/nmt-2018-0001

DO - 10.2217/nmt-2018-0001

M3 - Review article

C2 - 29564954

AN - SCOPUS:85054350584

SN - 1758-2024

VL - 8

SP - 73

EP - 80

JO - Neurodegenerative disease management

JF - Neurodegenerative disease management

IS - 2

ER -

The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this